^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers
Excerpt:
...Previous tumor samples or fresh tumor tissue biopsy samples can be provided, and any of the following biomarkers are confirmed positive by the central laboratory: 1)PD-L1 positive: defined as PD-L1 staining positive at any intensity in ≥5% tumor cells (TC) or ≥10% immune cells (IC); 2)Epstein-Barr virus (EBV) positive: defined as positive for EBV-encoded small RNA in situ hybridization (EBER-ISH); 3)Tumor mutation burden-high (TMB-H): tumor tissues will be detected by whole exome sequencing (WES), with tumor mutation burden ≥12 Muts/Mb; 4)Microsatellite instability-high (MSI-H): Tumor tissue is tested by whole exome sequencing (WES) to confirm MSI-H positivity; 6....
Trial ID:
Source:
Title:
A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)
Excerpt:
......
Trial ID:
More C2 evidence
Source:
Title:
A prospective multicenter clinical study for Toripalimab combined with SOX regimen in perioperative treatment of EBV (+) or MSI-H locally advanced gastric cancer
Excerpt:
...ORR - ORR; Pathological response rate - Pathological response rate; Safety - Safety; DFS - DFS; Quality of life improvement - Quality of life improvement; Expression level of PD-L1, tumor mutation load - Expression level of PD-L1, tumor mutation load...
Trial ID:
Less C2 evidence
Source:
Title:
Effect of reducing the number of neoadjuvant chemoimmunotherapy cycles on clinical efficacy in locally advanced PD-L1 positive gastric cancer: A single center phase 2 study.
Published date:
05/25/2023
Excerpt:
Among these 51 patients, pCR was got in 16 patients and the pCR rate was 31.4%, MPR rate was 66.7%. Further analysis according to the expression of PD-L1 is shown...Neoadjuvant therapy with FLOT plus toripalimab is safe and effective in locally advanced gastric cancer...
Secondary therapy:
FLOT
DOI:
10.1200/JCO.2023.41.16_suppl.e16074
Trial ID:
